Macular Telangiectasia (MT)
Macular Telangiectasia (MT) is a condition that affects the macula, leading to the loss of central vision. This disease occurs due to issues with the small blood vessels surrounding the fovea. Located in the center of the macula, the fovea provides the sharp central vision necessary for tasks such as reading. Our company is well-equipped to address your drug and therapy development requirements in Macular Telangiectasia therapy.
Introduction to Macular Telangiectasia
Macular telangiectasia type 2 is a rare, bilateral, degenerative eye disease that affects the macula, leading to progressive loss of central vision. The prevalence of MacTel type 2 is estimated to be between 0.02% and 0.1% in the general population. Recent studies indicate that this condition is primarily observed in individuals between the ages of 50 and 70, and it is associated with alterations in the retinal vasculature and neurodegeneration.
Pathogenesis of Macular Telangiectasia
Macular Telangiectasia is primarily considered a neurodegenerative disease affecting the Müller cells, which play a crucial role in maintaining retinal integrity and function. The dysfunction of these cells leads to atrophy and disorganization of the outer retina, causing photoreceptor loss and vascular anomalies. Genetic factors and metabolic defects, such as those affecting serine biosynthesis, are also implicated in the disease's pathogenesis.
Fig. 1 Fundus photograph and Corresponding angiogram image. (Kedarisetti, K.C., et al., 2022)Molecular Diagnostics of Macular Telangiectasia
- Advancements in molecular biology have led to the discovery of specific biomarkers associated with MT, including apolipoprotein E (ApoE) and cystatin C.
- Genetic testing can identify mutations or genetic variants associated with MT. Whole exome sequencing (WES) and targeted gene panels are used to detect genetic predispositions to the disease.
Therapeutics Development of Macular Telangiectasia
For Macular Telangiectasia, small molecule drugs aim to address the underlying mechanisms of the disease, such as retinal degeneration, vascular abnormalities, and neuroprotection. CNTF is a neuroprotective agent that has shown promise in treating retinal degenerative diseases.
Gene therapy strategies focus on delivering therapeutic genes to the retina to address the underlying causes of the disease. Researchers are investigating CRISPR/Cas9 to correct genetic defects in retinal cells, potentially providing a permanent solution to genetic causes of Macular Telangiectasia.
Cell therapies involve transplanting healthy cells into the retina to replace or support damaged cells, aiming to restore or preserve retinal function. Transplantation of RPE cells derived from human embryonic stem cells (hESCs) is being explored to replace the dysfunctional RPE in Macular Telangiectasia.
In MT, mAbs can be used to target pathogenic proteins or pathways that contribute to retinal degeneration and vascular abnormalities. Vascular endothelial growth factor (VEGF) plays a role in abnormal blood vessel growth and leakage in Macular Telangiectasia.
Our Services
Our company adopts a partnership-driven approach. We collaborate closely with clients to craft tailored, innovative Macular Telangiectasia therapy strategies and ensure robust support throughout the process.
Platforms of Macular Telangiectasia Therapy Development
Animal Models of Macular Telangiectasia
We have established expertise in developing and utilizing relevant animal models that closely mimic the disease characteristics and response to therapy. These models enable us to evaluate the safety and efficacy of potential therapies.
| Non-Genetically Engineering Models | ||
| We provide diverse model choices customized to meet specific research needs related to Macular Telangiectasia. These models allow researchers to simulate and study the complex biological processes associated with Macular Telangiectasia. | ||
| Optional Models |
|
|
| Genetically Engineered Models | ||
| Our expertise in genetic engineering techniques, such as CRISPR/Cas9 technology, allows us to generate accurate and reliable models that recapitulate the genetic alterations observed in human Macular Telangiectasia. | ||
| Optional Models |
|
|
| Optional Species | Mice, Rats, Non-human primates, Others | |
In addition to these models, our comprehensive services encompass other models that target specific signaling pathways and molecular targets.
If our services align with your goals, please contact us for more details.
References
- Jayasri, P. and Stephen, A.M., "A complete clinical review of idiopathic macular telangiectasia." Oman J Ophthalmol, (2023). 16(3): p. 421-426.
- Kedarisetti, K.C., et al., "Macular Telangiectasia Type 2: A Comprehensive Review." Clin Ophthalmol, (2022). 16: p. 3297-3309.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.